Cardiol Therapeutics Inc.
CRDL · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.23 | 0.33 | 0.06 | -0.70 |
| FCF Yield | -19.04% | -35.08% | -63.23% | -23.31% |
| EV / EBITDA | -2.53 | -1.77 | 0.03 | -0.70 |
| Quality | ||||
| ROIC | -161.84% | -79.07% | -79.07% | -40.03% |
| Gross Margin | 0.00% | 0.00% | 0.00% | -179.87% |
| Cash Conversion Ratio | 0.68 | 0.90 | 0.88 | 0.74 |
| Growth | ||||
| Revenue 3-Year CAGR | – | -100.00% | – | – |
| Free Cash Flow Growth | 0.64% | 7.51% | -15.84% | -156.96% |
| Safety | ||||
| Net Debt / EBITDA | 0.76 | 1.65 | 1.93 | 3.37 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -14,852.00 | -13,857.78 | -8,288.91 |